| Medication | n (%) |
---|---|---|
Total number of patients | 3316 | |
Concomitant administration of lipid-lowering drug during the study | Â | |
No concomitant drug | 3149 (95.0%) | |
Concomitant administration | 167 (5.0%) | |
   statin |  | 119 (3.6%) |
   others |  | 48 (1.4%) |
diabetes drug administration before and during the study | Â | |
   -Before- | -During- |  |
   Not taken | Not taken | 818 (24.7%) |
   Not taken | Taken | 521 (15.7%) |
   Taken | Not taken | 106 (3.2%) |
   Taken | Taken | 1871 (56.4%) |
No concomitant diabetes drug during the study | 924 (27.9%) | |
Concomitant treatment with diabetes drug during the study | 2392 (72.1%) | |
Single treatment with: | Â | |
   Sulfonylurea |  | 732 (22.1%) |
   Glinide |  | 188 (5.7%) |
   Alpha-glucosidase inhibitor |  | 169 (5.1%) |
   Biguanide |  | 93 (2.8%) |
   Thiazolidine |  | 49 (1.5%) |
   Insulin |  | 156 (4.7%) |
Combination therapies: | Â | |
   Sulfonylurea + alpha-glucosidase inhibitor |  | 229 (6.9%) |
   Sulfonylurea + biguanide |  | 212 (6.4%) |
   Sulfonylurea + thiazolidine |  | 91 (2.7%) |
   Other |  | 473 (14.3%) |